This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
A retrospective study was performed, based on administrative data from 13 United Health Care-affiliated plans. The data for patients with full 21-month follow-up (9 months before and 12 months after the index event) were included in analysis.
Analysis of effectiveness
The primary effectiveness measures used in this retrospective database study were asthma-related ED visits and asthmarelated hospitalisation rates.
The mean age of patients in the ZA group was 39.4 years; this was higher than that in the FP patients, 33.2 years. A higher proportion of the ZA patients had had a preindex event compared to FP: ED visits 8.7% and asthma hospitalisation 2.9% versus ED visits 6.1% and asthma hospitalisation 3.3%. The baseline rates for ED visits and hospitalisation were higher with increasing doses of FP.
The study estimates were adjusted for differences in baseline characteristics using the models described previously.
Effectiveness results
Compared with ZA, the adjusted OR for FP was 0.30 (95% confidence interval, CI: 0.11 -0.85; P=0.0232) for hospitalisation, and 0.51 (95% CI: 0.26 -1.01; P=0.0546) for ED visits.
The adjusted OR of either event was 0.49 (95% CI: 0.26 -0.92; P=0.0262).
The ORs for ED visits consistently favoured the 44, 110 and 220 microg doses of FP, but only the 220 microg dose was statistically significant, (p=0.0289).
The ORs for hospitalisations also consistently favoured all three FP doses.
Clinical conclusions
Inhaled FP produces a significant reduction in the number of combined hospitalisations and ED visits than ZA, in the treatment of patients with a diagnosis of asthma who are beginning maintenance therapy.
Modelling
A logistic regression was used to adjust the odds ratios (ORs) of visits to emergency departments (ED) or hospitalisation events for FP users, compared with ZA users. The ORs were adjusted for age, gender, preindex health care costs, preindex co-morbidities (chronic obstructive airway disease), preindex concomitant asthma medications (beta-agonists and oral corticosteroids), and preindex ED visits or hospitalisation.
A linear regression was used to adjust the difference in monthly costs per treated patient between the postindex and preindex periods for FP users, compared with ZA users. The changes in costs were adjusted for age, gender, preindex health care costs, preindex co-morbidities, and preindex concomitant asthma medications.
Measure of benefits used in the economic analysis
The authors did not derive a measure of health benefit. The study was therefore categorised as a cost-consequences analysis.
Direct costs
The costs were incurred over a period less than 2 years and no discounting was necessary. The costs were analysed on the basis of patients' charges. The costs included asthma pharmacy costs, total pharmacy costs, annual prescription
